Javier Martinez-Poles

Javier Martinez-Poles


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2018 in Toxins
Verified
Journal Article
Open access
PDF file
JMJavier Martinez-Poles
Javier Martinez-Poles
VNVelina Nedkova-Hristova
Velina Nedkova-Hristova
JEJosé Bernardo Escribano-Paredes
José Bernardo Escribano-Paredes
SGSebastián García-Madrona
Sebastián García-Madrona
ENElena Natera-Villalba
Elena Natera-Villalba
AAAraceli Alonso-Canovas
Araceli Alonso-Canovas
Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients’ perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.

15 October 2020 in Clinical Neuroradiology
Verified
Journal Article
Closed access
PDF file
JMJavier Martinez-Poles
Javier Martinez-Poles
RTRafael Toledano
Rafael Toledano
AJAdolfo Jiménez-Huete
Adolfo Jiménez-Huete
IGIrene García-Morales
Irene García-Morales
AAAngel Aledo-Serrano
Angel Aledo-Serrano
AGAntonio Gil-Nagel
Antonio Gil-Nagel

29 October 2024 in Epilepsia Open
Verified
Journal Article
Open access
VVVicente Villanueva
Vicente Villanueva
EVEsther González Villar
Esther González Villar
AFAlejandro Fernandez‐Cabrera
Alejandro Fernandez‐Cabrera
JZJorge Zurita
Jorge Zurita
FLFrancisco J. Lopez‐Gonzalez
Francisco J. Lopez‐Gonzalez
JSJosé M. Serratosa
José M. Serratosa
Objective: This study investigated the effectiveness and tolerability of brivaracetam (BRV) monotherapy in a large series of patients with epilepsy.Method: This was a multicenter, retrospective, observational, non‐interventional study in 24 hospitals across Spain. Patients aged ≥18 years who started on BRV monotherapy, either as first‐line or following conversion, at least 1 year before database closure were included. Patients were evaluated at baseline and at 3, 6 and 12 months after initiation of BRV monotherapy, in accordance with usual clinical practice at these centers. Data were collected retrospectively from patients' individual charts by participating physicians. The primary effectiveness and safety endpoints were the percentage of seizure‐free patients 1 year after initiation of BRV monotherapy and the proportion of patients reporting adverse events (AEs) over the complete follow‐up period. Retention rates and subpopulation analysis (levetiracetam switchers, elderly and different etiologies) were also investigated.Results: A total of 276 patients were included (48 with BRV as first‐line monotherapy and 228 who converted to BRV monotherapy). The overall retention rate in monotherapy at 12 months was 89.9% (87.5% for first‐line monotherapy group; 90.4% for conversion‐to‐monotherapy group). Seizure‐freedom rates at 12 months were 77.8% (75% for first‐line monotherapy group; 78.4% for conversion‐to‐monotherapy group). AEs occurred in 39.5% of patients at 12 months (35.4% for first‐line monotherapy group; 40.4% for conversion‐to‐monotherapy group). Most AEs were mild‐to‐moderate. The most frequent AEs were irritability (12.3%) and dizziness (10.1%). The most frequent AEs leading to BRV withdrawal were dizziness (1.8%) and memory problems (1.4%). Similar outcomes in terms of effectiveness and tolerability of BRV monotherapy were observed in patients switching from levetiracetam, those with different epilepsy etiologies, and elderly patients.Significance: BRV was effective and well tolerated both as first‐line monotherapy and following conversion to monotherapy in a real‐world setting of patients with epilepsy.Plain Language Summary: The goal of the medical treatment of epilepsy is to ensure best possible patient quality of life, by maximizing seizure control and minimizing medication toxicity. Brivaracetam (BRV) is a new‐generation epilepsy treatment that is well tolerated by patients. In our study, monotherapy with BRV reduced seizures in patients who had not received other treatments and in patients who switched from a previous treatment to BRV monotherapy. BRV was well tolerated and also effective in sensitive patients (i.e., the elderly and those who had epilepsy caused by a brain tumor or a brain injury).

29 May 2019 in Revue Neurologique
Verified
Journal Article
Closed access
JEJ.B. Escribano-Paredes
J.B. Escribano-Paredes
AJA. Jimenez-Escrig
A. Jimenez-Escrig
VNV. Nedkova-Hristova
V. Nedkova-Hristova
JMJavier Martinez-Poles
Javier Martinez-Poles
SGS. García-Madrona
S. García-Madrona
GRG. Rebolleda
G. Rebolleda

14 January 2020 in Neurology
Verified
Journal Article
Open access
PDF file
JMJavier Martinez-Poles
Javier Martinez-Poles
JEJosé Bernardo Escribano-Paredes
José Bernardo Escribano-Paredes
SGSebastián García-Madrona
Sebastián García-Madrona
VNVelina Nedkova-Hristova
Velina Nedkova-Hristova
AJAdriano Jiménez-Escrig
Adriano Jiménez-Escrig

14 August 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JMJavier Martinez-Poles
Javier Martinez-Poles
RTRafael Toledano
Rafael Toledano
AAAngel Aledo-Serrano
Angel Aledo-Serrano
KKKlaus Korn
Klaus Korn
RCRoland Coras
Roland Coras
AGAntonio Gil‐Nagel
Antonio Gil‐Nagel